RxDoctor Payments Data

Digant Nanavati, MD

Family Medicine · Syracuse, NYNPI 1811959935

Payments from drug & device makers

$26,355in general payments, 2019–2025

Across 1,643 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • Pfizer$2K
  • GSK$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$26,18799%
  • Education$1681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)155$2,114
Amgen(2 entities)103$2,089
Pfizer179$1,982
GSK137$1,963
Novo Nordisk141$1,740
AstraZeneca(2 entities)53$1,692
Lilly USA, LLC97$1,417
Astellas Pharma US Inc57$1,074
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC73$998
Boehringer Ingelheim49$882
Bayer51$877
Amarin Pharma, Inc.50$801
Teva Pharmaceuticals USA, Inc.45$654
Johnson & Johnson22$584
Shield Therapeutics Inc31$533
Sanofi-aventis U.S. LLC25$437
Novartis25$393
Merck20$330
Exact Sciences16$320
Currax Pharmaceuticals LLC20$315
Otsuka America Pharmaceutical, Inc.20$301
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$284
Biohaven Pharmaceutical Holding Company Ltd.24$269
Alnylam Pharmaceuticals Inc.13$259
Biohaven Pharmaceuticals, Inc.20$234
Esperion Therapeutics, Inc.12$229
Abbott15$227
Corcept Therapeutics10$219
Takeda Pharmaceuticals U.S.A., Inc.18$218
Sumitomo Pharma America, Inc.11$197
Kowa Pharmaceuticals America, Inc.8$156
Orexo US, Inc.9$154
Ardelyx, Inc.5$147
Corium, LLC10$142
Nestle Healthcare Nutrition Inc.7$131
Regeneron Healthcare Solutions, Inc.1$125
Axsome Therapeutics, Inc.5$109
Grifols USA, LLC6$105
Paratek Pharmaceuticals, Inc.6$96
Alk-abello, Inc3$93
Daiichi Sankyo Inc.5$92
Sun Pharmaceutical Industries Inc.4$77
Intuitive Surgical2$77
Arbor Pharmaceuticals, Inc.5$75
Insulet Corporation3$71
Idorsia Pharmaceuticals US Inc3$70
Verona Pharma, Inc.4$69
ANI Pharmaceuticals, Inc.3$68
Phathom Pharmaceuticals, Inc.4$61
Sanofi Pasteur Inc.3$60
Mylan Specialty L.p.4$55
Seqirus USA Inc2$45
Almatica Pharma LLC2$45
Collegium Pharmaceutical, Inc.3$45
Dexcom, Inc.2$44
Aimmune Therapeutics, Inc.2$41
ARS Pharmaceuticals Operations, Inc.2$38
Tolmar, Inc.2$34
IBSA Pharma Inc.2$33
Supernus Pharmaceuticals, Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,355 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$286,375
Medicare patients
360
Services billed
7,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide261$419,284
EliquisApixaban158$167,976
JardianceEmpagliflozin111$159,699
MounjaroTirzepatide74$110,759
JanuviaSitagliptin Phosphate93$101,002
MyrbetriqMirabegron67$65,814
TrulicityDulaglutide32$64,320
UbrelvyUbrogepant33$48,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$48,345
FarxigaDapagliflozin Propanediol41$47,946
WegovySemaglutide30$42,747
ZenpepLipase/Protease/Amylase17$42,721
VascepaIcosapent Ethyl78$42,222
XareltoRivaroxaban44$37,645
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$29,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,740$462,030291 claims
Boehringer IngelheimJardiance, Spiriva Respimat$882$180,619134 claims
Lilly USA, LLCMounjaro, Trulicity$1,417$175,079106 claims
PfizerEliquis$1,982$167,976158 claims
MerckJanuvia, Janumet Xr, Janumet, Lagevrio (Eua), Steglatro$330$161,736164 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,963$98,983138 claims
AbbVieUbrelvy, Creon, Linzess$2,114$82,06174 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,692$80,664110 claims
Astellas Pharma US IncMyrbetriq$1,074$65,81467 claims
Johnson & JohnsonXarelto, Invokana$584$56,17055 claims
Aimmune Therapeutics, Inc.Zenpep$41$42,72117 claims
AmgenProlia$2,089$20,03911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →